Until recently treatment options for
ovarian cancer were limited to surgery
and chemotherapy. However in 2011, the
European Commission (EC) announced
the approval of a biological therapy in
combination with standard chemotherapy
(carboplatin and paclitaxel) as initial
treatment for advanced (stages III B, III C
and IV) epithelial ovarian, fallopian tube,
or primary peritoneal cancer. This marked
the first new effective treatment option for
women with advanced ovarian cancer in 15
years. Radiotherapy is not frequently used
to treat ovarian cancer